Search form


Press Releases

Axcan Pharma to Host Analyst/Investor Luncheons in New-York and Montreal

Jan 15, 2004 - 12:00 ET

Axcan Pharma to Host Analyst/Investor Luncheons in New-York and Montreal

MONT SAINT-HILAIRE, Quebec--Axcan Pharma Inc. ("Axcan" or the "Company") announced
today its upcoming Analyst/Investor Luncheons in New-York (February 17, 2004) and
Montreal (February 19, 2004).

Léon F. Gosselin, President and Chief Executive Officer of Axcan and David W. Mims,
Executive Vice President and Chief Operating Officer of the Company, will give a
corporate presentation followed by a question and answer period.

The luncheons will also feature Dr. François Martin, Senior Vice President, Scientific
Affairs of Axcan and Dr. Patrick Colin, Vice President, Research and Development, who
will discuss various programs in Axcan's development pipeline.

An audio webcast will be available live and archived for 30 days at the Axcan website

Axcan is a leading specialty pharmaceutical company involved in the field of
gastroenterology. The Company markets a broad line of prescription products sold for
the treatment of symptoms in a number of gastrointestinal diseases and disorders such
as inflammatory bowel disease, irritable bowel syndrome, cholestatic liver diseases
and complications related to cystic fibrosis. Axcan's products are marketed by its own
sales force in North America and Europe. Its common shares are listed on the Toronto
Stock Exchange under the symbol "AXP" and on the NASDAQ National Market under the
symbol "AXCA".

Isabelle Adjahi
Director, Investor Relations					
Axcan Pharma Inc.
Tel: (450) 467-2600 ext. 2000